Corticosteroids are the mainstay of treatment for hospitalized patients with acute severe ulcerative colitis (ASUC). However, whether the addition/continuation of mesalamine with corticosteroids ...

LIALDA (mesalamine) with MMX technology -- the first oral once-daily mesalamine for active, mild to moderate ulcerative colitis -- now available Basingstoke, UK and Philadelphia, PA, US – March 19, ...

Cellix Biosciences Inc. ("Cellix Bio"), a development-stage pharmaceutical company, today announced successful completion of a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and ...

Corticosteroids are effective at inducing remission in patients with ulcerative colitis (UC); however, it is not known if adding mesalamine confers additional benefits in the acute setting. In a ...

“Given the minimal adverse events, we recommend that curcumin be considered as an adjunct to mesalamine in the treatment of UC.” Adjunctive therapy with curcumin was found to provide a greater ...

The FDA has approved Lialda (mesalamine), a once-daily oral formulation of mesalamine for the induction of remission in patients with active, mild-to-moderate ulcerative colitis. Lialda tablets have a ...

Do DPP-4 Inhibitors Harm Patients with T2DM and Heart Failure? The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed ...

Basingstoke, UK and Philadelphia, US – January 16, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDA TM ...

Please provide your email address to receive an email when new articles are posted on . Sun Pharmaceutical Industries received FDA approval of its abbreviated new drug application for mesalamine ...

Eugenia Uche-Anya, MD, MPH, gastroenterology fellow at Massachusetts General Hospital, discusses the results of the case and important points to keep in mind when treating patients with mild UC: ...

A colon affected by ulcerative colitis with massive pseudopolyps. A new clinical guideline from the American Gastroenterological Association focuses on the medical management of patients with ...